0001267813false00012678132024-11-142024-11-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 14, 2024

Marinus Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

 

001-36576

 

20-0198082

(State or other jurisdiction of incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

, Radnor, PA

5 Radnor Corporate Center, Suite 500

100 Matsonford Rd, Radnor, PA

 

19087

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (484) 801-4670

__________________________________________________________________
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001

MRNS

Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 14, 2024, each of Charles Austin, Saraswathy V. Nochur, Ph.D. and Sarah Noonberg, M.D., Ph.D., resigned from the Board of Directors of Marinus Pharmaceuticals, Inc. (the “Company”), effective immediately. Mr. Austin’s, Dr. Nochur’s and Dr. Noonberg’s resignations were not due to any disagreement with the Company on any matter relating to its operations, policies or practices. Following the resignations, the Board of Directors of the Company decreased the authorized number of directors of the Company from nine directors to six directors.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MARINUS PHARMACEUTICALS, INC.

Date: November 15, 2024

/s/ Steven Pfanstiel

Steven Pfanstiel

Chief Operating Officer, Chief Financial Officer and Treasurer

v3.24.3
Document and Entity Information
Nov. 14, 2024
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Nov. 14, 2024
Entity File Number 001-36576
Entity Registrant Name Marinus Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 20-0198082
Entity Address State Or Province PA
Entity Address, Address Line One 5 Radnor Corporate Center
Entity Address, Adress Line Two Suite 500
Entity Address, Address Line Three 100 Matsonford Rd
Entity Address, City or Town Radnor
Entity Address, Postal Zip Code 19087
City Area Code 484
Local Phone Number 801-4670
Title of 12(b) Security Common Stock, par value $0.001
Trading Symbol MRNS
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001267813
Amendment Flag false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false

Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
Von Okt 2024 bis Nov 2024 Click Here for more Marinus Pharmaceuticals Charts.
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
Von Nov 2023 bis Nov 2024 Click Here for more Marinus Pharmaceuticals Charts.